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Abstract
As with many other aspects of the modern world, in healthcare, the explosion of data and
resources opens new opportunities for the development of added-value services. Still, a num-
ber of specific conditions on this domain greatly hinders these developments, including ethical
and legal issues, fragmentation of the relevant data in different locations, and a level of (meta)
data complexity that requires great expertise across technical, clinical, and biological domains.
We propose the Patient Dossier paradigm as a way to organize new innovative healthcare ser-
vices that sorts the current limitations. The Patient Dossier conceptual framework identifies the
different issues and suggests how they can be tackled in a safe, efficient, and responsible way
while opening options for independent development for different players in the healthcare sec-
tor. An initial implementation of the Patient Dossier concepts in the Rbbt framework is available
as open-source at https://github.com/mikisvaz and https://github.com/Rbbt-Workflows.
Introduction
Data in medicine
Data that can be relevant to healthcare are ubiquitous, extensive, and extremely valuable. This
is due to several factors: the dramatic reduction in costs of next-generation sequencing (NGS)
and its increasing scope of application, which has helped “omics” penetrate strongly into clini-
cal practice [1–3]; the adoption of electronic health records (EHRs), which are becoming a
vehicle to share the clinical histories of patients in a homogeneous and interoperable way [4,5];
and the increasing use and connectivity of devices such as medical monitors and personal
wearables, which are recording biometric and lifestyle information about patients as well as
the general population [6,7]. Like many other areas of the modern world, the advances in data-
centric services—articulated around big data, deep learning, artificial intelligence, increased
computation power, and more sophisticated approaches to managing data and computational
infrastructures—are exerting a phenomenal transformative force on healthcare.
Permed in cancer research
One of the flagships of data-centric healthcare is personalized medicine (PerMed), which
holds the promise of realizing better health outcomes for patients by customizing treatment to
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y Bioinformáticos PT13/0001/0030. Additional
support came from the Lenovo - BSC Master
Collaboration Agreement (2015) and from the IBM-
BSC Deep Learning Centre (2016). The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist
their individual characteristics [8–10]. Genomics have brought us numerous examples of
PerMed, especially in its application to cancer. For instance, the initial understanding the
molecular mechanisms of tumorigenesis down to the effect of individual mutations enabled
the development of targeted therapies that have made significant progress eliciting tumor
remission. Even if new challenges of acquired resistance or clonal heterogeneity have emerged,
the current developments clearly show the importance of precise molecular information.
Indeed, in the field of cancer, a number of additional genomic applications are being devel-
oped to consolidate the initial breakthroughs of targeted therapies, opening treatment avenues
like immunotherapies or combinatorial therapies [11,12]. Furthermore, the variability of drug
response in terms of efficacy or toxicity can often be explained by genomic differences. For
instance, the drug warfarin, a medicine that acts as an anticoagulant, shows extreme differ-
ences in the magnitude of its effect, with severe health consequences, owing to particular geno-
mic variants in the patient [13].
Other uses of healthcare data
Data analytics is influencing other areas of healthcare beyond PerMed. With the recent
advances in artificial intelligence and personal assistants, holistic lifestyle data could be used to
provide customized counselling not only to patients but to the general public regarding day-
to-day lifestyle choices [14]. Wearable medical monitors could anticipate clinical episodes and
alert the patient or first responders, and the process of recruitment for medical studies and
clinical trials could be facilitated by functionalities such as obtaining consent and processing
information with the highest guarantees; at a different scale, population-level biometrics or
lifestyle changes could inform policy decisions by healthcare agencies [15]. In other words, the
accessibility of patient information is making possible the creation of new high-value services.
However, tapping the full potential of data analytics in healthcare remains elusive. The wealth
of heterogeneous information scattered across distributed data sources (genomics, clinical his-
tories, lifestyle, environment, etc.) needs to be gathered, integrated, and built into value-added
services. Developing effective systems for handling all of that highly valuable information faces
important challenges related to the privacy of the data.
Privacy issues
Data are produced, managed, and owned by different entities: hospitals, clinics, companies, or
the users themselves. Exploiting these data needs to meet strict guarantees in terms of privacy
and security for the patient, as well as intellectual property and consent of use. The General
Data Protection Regulation (GDPR), put forward by the European Union and assimilated by
other entities around the world, faces these challenges by providing guidelines that all data-
centric services must follow, including those in healthcare.
Technical challenge
Beyond the data security issues, the nature of the different data types poses very specific techni-
cal challenges. For instance, omics data often require dealing with NGS reads, which can be
extremely bulky and challenging to move around; they are also very sensitive to reidentifica-
tion attacks that could pose severe threats to patient privacy [16,17]. Wearable devices such as
medical monitors provide streams of data that may need be analyzed on the fly to provide real-
time responses [18,19]. Managing streaming data this way challenges the habitual infrastruc-
ture setups. Data in EHRs and other medical documents are often not fully homogenized into
standard terminologies, and actually, often, the most interesting information is expressed in a
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free-text format that needs to be processed using natural language processing (NLP) tech-
niques [20,21].
The combination of security and privacy regulations, infrastructure challenges, and the
challenges in data analysis methods themselves are crucial obstacles, especially in building
healthcare services to exploit patient data in a holistic way.
Here, we propose a new conceptual framework to structure the different operations
involved in bringing forward these services safely, reliably, and efficiently. We describe the
Patient Dossier as a new organizing concept to tackle all these challenges.
Outlook of future applications
The concept of Patient Dossier aims at fulfilling the applications, features, and functionalities
that we foresee as critical for the healthcare future.
• Data from the patient’s clinical history will be more accessible, allowing a better engagement
of the patients with healthcare services across regions and administrations.
• Proposals of personalized treatment will be facilitated thanks to the availability of quality
bioinformatics recipes.
• The hassle involved in moving around large datasets and finding the right expertise to pro-
cess them, such as NGS from healthcare providers, will be improved to help these technolo-
gies penetrate further in the healthcare system.
• The analysis of healthcare data on behalf of the patient will be improved by opening these
analyses to the other parties, including industry and public health systems, thanks to the
safety guarantees provided by the technological aspects of the framework and its compliance
with legal frameworks such as the GDPR.
• Patients will become managers and controllers of their own data, based on the confidence in
their engagement with the healthcare data economy with a good level of trust and account-
ability, thanks to the standardization and simplification of the data handling mechanisms.
• Population-level analysis can be built through the Patient Dossier if the necessary mecha-
nisms to manage consent are set in place. The results of a population-level analysis might be
aggregate statistics across the population, which the interested parties will receive without
the need to have access to the individualized information.
• Indeed, a number of advances are already in progress that should help find solutions to the
main technical challenges:
� The regulatory framework is now being defined thanks to the GDPR; the technical sup-
port for these operations is in place thanks to the expansion of cloud providers, workflow
enactment systems, and containerization systems.
� International efforts, such as the Global Alliance for Genomics and Health (GA4GH), are
addressing normalization aspects essential for the integrated functioning of the system,
while in the numerous projects on cancer, aging, rare diseases, or drug synergies, acade-
mia and companies are joining forces to develop analysis methodology and strategies.
� Large-scale infrastructures, i.e., European Bioinformatics Infrastructure (ELIXIR), or
community efforts such as Galaxy (https://galaxyproject.org), are dedicated to maintain-
ing repositories of safe and vetted software recipes and workflows, making them easily
accessible, as well as to developing systems to make data findable, accessible, interopera-
ble and reusable (FAIR) [22].
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However, the availability of data is still problematic, because it is not obvious how these
data are localized, especially when the question involves data across different providers. Ques-
tions such as assessing whether data are relevant, whether data are up-to-date, or whether
there are associated legal and ethical issues add additional challenges. Additionally, when med-
ical questions involve processing data across multiple sites, a mechanism to orchestrate this
deployment is required, whether it is entirely distributed through a peer-to-peer communica-
tion over federated entities or requires some level of centralization.
Patient Dossiers
Currently, services around medical data are focused on particular datasets, for instance, variant
analysis for NGS data; sharing of EHR and other medical documents between hospital depart-
ments; and weight, activity, and biometric data analysis for sports monitoring wearables. The
mechanisms to build high-value services on top of these, potentially incorporating information
from each, are hindered by technical and ethical issues but most of all, in our opinion, by the
lack of a simple yet ambitious vision of how these services could be described and realized.
Direct questions as the core of medical services
Specific medical questions are the logical starting point to nucleate and build patient-specific
services around. For example, has the patient received a particular treatment? Is he/she actively
exercising? What was his/her blood pressure on the last check-up? Does the patient harbor a
particular germline variant? When designing services, it would be convenient to think in
terms of these questions and not to be concerned with the details about where this information
resides or how it is computed. At the same time, it would be good to have some certainty that
when the answer to these questions involves computational pipelines, such as when character-
izing a patient genotype, the required pipelines follow guidelines that ensure good quality and
homogeneous, comparable, and interoperable results.
Defining the Patient Dossier
We define the “Patient Dossier” as the collection of particular questions that can be asked (and
answered) about a patient at the current time. These questions can be very diverse, but they all
should be able to be resolved by following some recipe, which will take into account the partic-
ularities of each case, such as what data are available. Usually, bioinformatics tools and pipe-
lines focus on processing, filtering, or inferring information out of data; they can often be
thought of as ingesting files in one format and producing a file in a different, more distilled for-
mat. For instance, an NGS pipeline would take files in FASTQ format and render a variant call
format (VCF) file. The Patient Dossier bridges the gap from these pipelines to an application
setting, for instance, when a clinician asks whether the subject has a particular variant that can
help explain his or her condition.
The Patient Dossier focuses on questions that a “human” operator might ask (e.g., a clini-
cian, a government agency, the patients themselves) as opposed to the more technical ques-
tions software tools would use to communicate, such as the availability of a given type of data
for a given patient or the format in which it is encoded. These later questions belong to how
the Patient Dossier is implemented but not to its interface. The questions defined in the Patient
Dossier provide a language that can serve as a point of understanding between pipeline devel-
opers and the final users, sparing the latter the need to get involved with the more technical
aspects. Complex queries involving different aspects of the patients’ health can be answered by
composing more basic queries from the Patient Dossier.
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Simple Patient Dossier queries
Some questions just involve simple queries, but how these queries are made may differ from
case to case. For instance, the answer to the question of the blood pressure on the last check-up
when issued within a hospital unit might involve a query to the hospital information system,
whereas when issued by a primary care system, it might involve accessing the information sys-
tem on the clinic where the patient took the test or even some intermediate data repository
where the user manages his or her medical information. Data need to be accessed through
interfaces or “drivers” that are able to communicate with the different data providers. This is
perhaps the most critical aspect of realizing the Patient Dossier and where the GDPR is more
relevant.
Security and ethical issues in the Patient Dossier
From an ethical and legal standpoint, issues of data security, patient confidentiality, and con-
sent of use also differ from question to question and from environment to environment. The
Patient Dossier provides the right level at which to describe and resolve these ethical and legal
issues. Each question in the dossier should explicitly state the information it delivers, which is
the subject of these considerations, regardless of the data that are used to source it. Consider,
for instance, the question of whether a particular lung tumor is driven by KRAS mutations, a
question which might be answered from some exome sequencing that was performed on a
tumor biopsy. The entire data set of NGS reads might be subject to strict access rules, because
even when anonymized, it could still be abused to reidentify the subject, whereas the interpre-
tation about what drives the tumor, based on a bioinformatics recipe, would not be subject to
such strict regulations because it does not pose such a direct risk to patient’s rights.
Provenance and data economy
The Patient Dossier should not only address the issues of data security, patient privacy, and
consent, it must also maintain the links on data provenance and ownership across the different
transactions and transformations, i.e., what data are owned by whom and how information
derived from it can be used for different purposes by third parties. When decisions are made
based on analysis of data, detailed provenance describing how the analysis is conducted pro-
vides assurances, accountability, and insight. Services can be built around the availability of
the data but also around how they are processed. In this sense, the Patient Dossier will be a
central piece of the data economy based on patient health data.
Computing, pipelines, and high-performance computing
Some of the questions in the Patient Dossier will involve expensive calculations. Coming back
to our example of the KRAS-driven lung tumor, the computations involved in figuring out
what drives a tumor from the exome sequencing NGS reads poses a significant computational
challenge. Not only are significant computational resources required but also an important
level of technical expertise. How these data are analyzed resembles laboratory protocols: it’s a
recipe composed of a series of steps that are designed to ensure reliable results.
By focusing on the medical questions and how they are answered as opposed to focusing on
the data files themselves (see Table 1), the Patient Dossier will become the place to organize
how these recipes are maintained and made accessible to the different parties. Maintaining
these recipes so that they meet with best practices in each field and incorporate the latest tech-
nological advances is a task that should be assumed by experts. Likewise, maintaining the
computational infrastructure to enact these recipes should be entrusted to specialized entities,
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such as cloud providers and HPC centers. In other words, to handle the systems for accessing
data, the Patient Dossier must rely on trustworthy and secure infrastructure to perform these
computations with the highest guarantees, involving the adequate software recipes and
computational resources able to prevent leakage of sensitive data and hardened against attacks
by malicious parties.
Implementing the Patient Dossier
The distributed scenario described previously requires implementations of the Patient Dossier
to be modular and adapted to the peculiarities of each different software environment. We
believe that an approach not tied to a single technical implementation of the Patient Dossier
will help adoption and should spark the development of a variety of solutions, sorting out the
specific implementation practicalities in each environment. We will discuss our own imple-
mentation of the Patient Dossier in a following section, but we would like to emphasize that
our definition should be general enough to encompass, to some extent, the mechanisms that
are already in place at many PerMed initiatives. Having said that, there are three things that we
believe are important to implementing a Patient Dossier and from which we would like to
extract some general recommendations.
Recipes as workflows
Workflows are increasingly popular in bioinformatics, with many alternative software tools to
implement and enact them. Some popular projects in workflow community are Nextflow
(https://www.nextflow.io/), Galaxy, common workflow language (CWL), and workflow defini-
tion language (WDL). Workflows commonly incorporate the idea that results get built in suc-
cessive steps, each step being a refinement of a previous one. This idea of progressively
building the final result through a sequence of steps is not new to informatics, because, for
example, it is the basis of the software compilation tool “make.” Just like a compiled applica-
tion binary developed in C gets progressively built from its smaller constituents, a general
question to the Patient Dossier will be built through a series of steps and implemented as a rec-
ipe in a workflow enactment tool. The parallel between the “make” tool and general workflows
has been noted elsewhere, for instance, in the Snakemake tool (https://snakemake.
readthedocs.io).
The Patient Dossier can then be grown out of data through the use of software recipes or
other smaller workflows. A convenient way to visualize a workflow that answers to Patient
Dossier questions will be a dependency tree like the one in Fig 1. Each node of the dependency
tree is a step in the workflow and represents a particular piece of data or information. These
nodes can be seen as Patient Dossier queries themselves with associated considerations of pri-
vacy and computational costs. Different nodes in the dependency tree can be reused for differ-
ent purposes, as shown in Fig 1. There is no need to enact all possible computations to
Table 1. Broad differences between the Patient Dossier and the current paradigm.
Current paradigm Proposal for the Patient Dossier
Basic object Data Medical questions
Processing
workflows
From file format to file format Medical question to question
Data processor On site of the user after gathering data, or using a
limited predefined set of processes on the data
provider
Distributed or brokered, guided by the
granularity of the questions and how they
compose
Exploitation Authorized data access Authorized question access
https://doi.org/10.1371/journal.pcbi.1007291.t001
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generate all the nodes in the graph, just what is required. Nodes might be already available if
they were required before or if these were precomputed as part of a data management policy.
All nodes in the graph in principle could be Patient Dossier queries, yet most likely some
would represent intermediate processing steps with no interest for the final user. Being able to
trace back a particular result through the dependency tree allows checking its provenance
when making important decisions.
Access to data and computing infrastructure
Not all the steps involved in resolving a Patient Dossier question need to be enacted in the
same location. Nowadays, the penetrance of virtualization and containerization technologies
allows the deployment of computations across the entire “computing continuum,” from edge
devices to cloud infrastructures and HPC resources. This distributed setup helps circumvent
Fig 1. Example query over the Patient Dossier. The user, a clinician in this case, interrogates the Patient Dossier of a cancer patient for the recommended therapies,
which is a particular node in the dependency tree. This, in turn, enacts a cascade of computations, because computing a node requires that other nodes be available. The
arrows between nodes represent information flowing and being transformed or processed by the different recipes; for instance, NGS reads get transformed into mutated
genes through variant calling and annotation pipelines. In this particular example, the recommended therapies result from considering clinical data and the list of mutated
genes. Clinical data get composed inside the hospital through queries to the HIS, including clinical history and laboratory tests results. The image shows a single hospital,
but data could potentially be aggregated from several hospitals and healthcare centers. The NGS data in this example were transferred to a computing center that took care
of calculating the mutated genes. Sensitive information resides in silos and may only be gathered under strict access controls, such as clinical information or NGS reads.
Nonsensitive information, such as the list of mutated genes or the set of drug therapy recommendations, might be accessed more widely through more lax access controls
(provided the patient information is anonymized), for instance, in population-level queries issued by a different user, such as a government institution deciding on
medical spending policy or a pharma company designing a clinical trial. HIS, hospital information system; NGS, next-generation sequencing.
https://doi.org/10.1371/journal.pcbi.1007291.g001
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many of the issues regarding data security and computational costs. For instance, a data con-
troller that holds very sensitive data may be able to export a safer version of these data in the
form of a distilled result through Patient Dossier recipes; this way, sensitive data never leave
the site. Likewise, sensitive data might travel through secure channels to a computational
resource, where they might collate with other sensitive data, to be processed by analytical
methods, and the final result delivered to the interested party; this way, there is no need to
trust the interested party with the sensitive data in the first place. The computational resource
should thus offer a hardened environment, perhaps disconnected from the internet and with
ephemeral storage, to ensure the highest guarantees protecting the patient data. Thanks to this
enhanced trust, medical devices and wearables used by patients will be able to provide timely
advice and health alerts or require medical assistance based on artificial intelligence models
running over constant streams of biometrics data without security or privacy risk.
Scheduling and data management policies
The way to answer a medical question through the Patient Dossier is to follow a defined step-
by-step recipe, which lays out how to process the data to arrive at that answer. However, the
entire recipe does not always have to be run at the time each question is formulated; complex
steps may be planned in a more appropriate way to prepare for future questions. For example,
when NGS data arrive at a compute facility, the policy of the center might dictate that the
alignment and variant calling tasks be scheduled immediately and plan how and for how long
the resulting files should be stored. These are realistic requirements, and the Patient Dossier
does not challenge them; it only orders them and makes them as explicit as possible in the
form of code (e.g., workflows). Some steps might involve a certain level of manual curation or
quality control; these need to be incorporated in the Patient Dossier as part of its code of
instructions in a way that will make it possible to preserve the provenance of the results and
reproducibility of the process. In summary, the Patient Dossier is designed to make the process
of answering complicated medical questions as seamless as possible, but it is also called to help
manage the complexities of modern biomedical data analysis by accounting for them explicitly
in its recipes.
The development ecosystem
Progress in delivering a new type of value-added healthcare services would be a collective
effort, so it is important that the Patient Dossier opens up participation to different players.
Our view of the Patient Dossier is that it must have roles for providers of computational
resources, data, secure data transmission mechanisms, analytical methods, and ancillary data
resources that help cast the patient data into context. The distributed nature of the Patient
Dossier should allow the protection of intellectual property while still maintaining provenance
and accountability information. A responsible and accountable engagement from all parties,
including industry, will promote innovation across a wide array of services catering to the
healthcare providers, administration, and patients. The development of software tools around
analytical methods, workflow enactment, and infrastructure management is currently very
active and progressing in huge strides, not only in the medical and bioinformatics communi-
ties. This reaffirms our idea that the implementation of the Patient Dossier should not be tied
to a specific implementation, at least for the time being, but rather a wealth of different solu-
tions should be fostered to match the previously mentioned requirements on flexible schedul-
ing and integral data management.
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Proof of concept: The implementation of the Patient Dossier in the Rbbt
framework
We have implemented the initial ideas behind the Patient Dossier in the workflow enactment
tool Rbbt (Ruby Bioinformatics Toolkit). The implementation includes the following:
• Building of results through a cascade of steps that form a dependency tree and the modular
architecture of functionalities, which can be manipulated independently. In Rbbt, task-spe-
cific workflows can be composed into larger workflows answering arbitrarily complex ques-
tions formulated in the Patient Dossier.
• Rbbt workflows, or parts of them, can be served through remote servers via REpresentational
State Transfer (REST) interfaces facilitating the deployment of complex workflows leverag-
ing functionalities that require specialized resources, require complicated setups, or are man-
aged by parties that wish to protect their intellectual property.
• Cloud or HPC resources can be directly used to deal with larger workloads. These alternative
deployment options can be configured transparently while maintaining provenance infor-
mation. For example, in the implementation of Rbbt for Pan-Cancer Analysis of Whole
Genomes (PCAWG), PCAWG-Scout [23] (the server exposing the functionalities to the
public) does not hold any sensitive data; instead, whenever it needs to build a result that
requires these sensitive data, it relays those steps to a second server, locked behind an institu-
tional firewall, which holds secure data and only serves back “safe” analysis results.
• Workflows are broken down into thematic workflow modules that can be combined to allow
a flexible deployment of computations and data. In Rbbt, this approach is used to deal with
questions involving privacy issues or large data size and costly processing workloads, like
when dealing with NGS data. The modular approach also allows workflow modules to be
maintained by different teams.
• The Rbbt workflow enactment tool allows the use of configuration options that are used by
different steps across the dependency tree, and it implements a strategy for the reuse of these
intermediate results, accounting for the configuration options and the step they are used in.
This allows an efficient exploration of configuration options, which can be helpful to validate
and double check results. For instance, the Rbbt genomic pipeline can be run entirely over
different genome builds, using different variant callers or different sets of filters to evaluate
how these affect the results.
• The implementation of the Patient Dossier in Rbbt is prepared to automatically save detailed
provenance of the complete process, including the configuration options used at each step,
avoiding registering omissions and errors when imputing these metadata.
• Updates of the results are triggered by the Rbbt framework if the underlying data dependen-
cies are updated, ensuring consistency. The complete dependency graphs can be grafted
from one system to another without breaking the provenance structure, building the founda-
tion to implement efficient data management and archiving strategies. For example, sensitive
parts of workflows—for instance, performing somatic variant calling—can be enacted in
hardened environments, and the portions of the dependency graph that are saved can be
grafted onto a different location to enable a whole other set of downstream analyses, such as
determining tumor clonal evolution or its mutational signatures.
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• The Patient Dossier requires a querying interface, and Rbbt implements these functionalities
through an expressive interface supporting command-line, HTML, or programmatic
operations.
To illustrate how the Patient Dossier concept has been mapped into the Rbbt, let us con-
sider the case of genomic analyses. The Rbbt offers the “Sample” workflow module, which is a
repository of many questions around molecular data from patients. Questions typical of the
Patient Dossier include what tumor suppressors and oncogenes have their function potentially
disrupted by mutations, which genes can be considered (possibly) totally nonfunctional (e.g., a
damaging mutation combined with a loss of heterozygosity due to copy number variation
(CNV) or a combination of two damaging mutations that could affect both alleles), which
transcription factors and signaling molecules seem to be active in the tumor, or what drug
treatments can be recommended or not to the patient based on this information. The Rbbt
Sample module leverages other workflows that perform more specific tasks. For instance, the
“Sequence” workflow module translates genomic mutations into protein mutations and finds
mutations over splicing sites or over regulatory regions.
Examples of Rbbt-implemented workflow modules that can address standard Patient Dos-
sier questions include the following: the Sequence module, in which specific tools can be
selected (such as the popular ANNOVAR [24] or variant effect predictor [VEP] [25]); the
“Structure” module, which calculates distances in the Protein Data Bank (PDB) structures of
proteins to find mutation clusters or mutations falling over regions of interest or in their close
proximity; and the “Mutation Signatures” module, which determines the mutation signatures
likely to have induced these mutations.
The Sample module has mechanisms to find the necessary information in specific locations
in the file system, but these mechanisms can be overridden to accommodate the details of dif-
ferent datasets; for instance, for queries on large datasets (such as the International Cancer
Genome Consortium [ICGC] data), the mutations can be gathered first from the ICGC data
hub and stored in the file system in the correct format. User’s datasets, in the form of FASTQ
files, are processed into VCF files using the high-throughput sequencing (HTS) workflow
module, following best practices defined in the community and using the appropriate auxiliary
data, such as the correct genome build, panel of normals controls, or the appropriate interval
files for the capture technology use. For the processing of NGS reads, the mechanisms issue
the work to the appropriate HPC environment, where the bulky and highly sensitive data are
subject to appropriate data management policies defined by the specific institutional data
management policies.
The Rbbt framework and all the workflow modules discussed here are open-source and can
be found in GitHub (https://github.com/mikisvaz and https://github.com/Rbbt-Workflows).
Rbbt has been developed with internal use in mind, so some expertise is required to set it up
and adapt it to the details of a particular infrastructure or a particular project. The more profi-
cient reader might be able to try it out, at least in part, with the help of the Rbbt documentation
(http://mikisvaz.github.io/rbbt/); a good place to start is the ICGC workflow module.
The Rbbt framework is a versatile and powerful tool for developers of methods, pipelines,
and infrastructure who know how to use it. It exemplifies some of the core elements in the
Patient Dossier, but—in addition to the fact that the documentation is too lacking for general
adoption, at least at the time of this writing—it still falls short of implementing the complete
picture. Its functionalities cover mostly NGS analyses, which are a particular part of the Patient
Dossier but not the only or necessarily the most interesting one. The ability to include infor-
mation from wearables and lifestyle is among the most promising features of the new para-
digm, and for these specific features, work needs to be done, in particular, to gather data from
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such resources. Rbbt is prepared to work with cohorts but has no mechanisms to deal with ad
hoc, on-demand, population-level analyses; for that, there needs to be mechanisms to identify
these potential subjects, obtain consent, etc. Some of these questions will be addressed by
metadata policies, such as the ones that inspired the FAIR principles; others will be worked out
as the GDPR develops. Finally, the Rbbt does not currently exemplify enough the harmonized
use of results stemming from different patient data sources, for instance, NGS and wearables.
In this regard, Rbbt has been used to simulate the signaling networks of cell lines, for which
cell-line data were used from different resources such as Cancer Cell Line Encyclopedia
(CCLE), Genomics of Drug Sensitivity in Cancer (GDSC), Achilles, and the MD Anderson
Cell Lines Project (MCLP) [26–29]; a much more challenging setting would be to perform
such integration when the different data sources are sensitive patient data held by different
entities (research institutions, hospitals, companies, etc.), and the computations are first dis-
tributed among them and then brokered into a secure cloud resource.
Conclusions
We describe the concepts behind the Patient Dossier, proposed as an interface between those
who design innovative healthcare services, those who implement the technological building
blocks, those who deal with legal and ethical implications, and those who look for business
opportunities with the final users, clinicians, biomedical scientists, and possibly patients in
mind. The point of communication is the actual questions that are asked about a patient,
adapting the paradigm of software design in which an application programming interface
(API) is used as a “contract” between different teams.
By laying out our vision of the Patient Dossier, we hope to provide a framework to commu-
nicate ideas and challenges between different communities with technologies that are largely
available in the field. To exemplify these concepts, we describe an initial implementation of the
Patient Dossier for handling genomic information in a Ruby framework called Rbbt.
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